Joshua Hexter

Joshua Hexter, listed as chief executive, appears in our data through filings on Oramed Pharmaceuticals Inc. shares, published by SEC (Form 4). Between 31 August 2021 and 1 October 2026, the trades on record add up to 15 filings.

Sales make up the whole of the open-market record (1 sale, €119k). Besides market trades, the filings include 13 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

The latest filing, published on 2 October 2026, reports an open-market sale of €119k in Oramed Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.